References
- Stahl, S M. Dopamine system stabilizers, aripiprazole and the next generation of antipsychotics, part 2. J Clin Psychiatry 2001; 62:923–924. [PUBMED], [INFOTRIEVE]
- Taylor, D M. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Prac 2003; 57:49–54.
- Freedman, R. Schizophrenia. N Eng J Med 2003; 349(18):1738–1749. [CROSSREF]
- Marder, S R, McQuade, R D, Stock, E, Kaplita, S, Marcus, R, Safferman, A, Saha, A, Ali, M, Iwamoto, T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res 2003; 61(2–3):123–136. [CROSSREF], [CSA]
- Abilify® (Aripiprazole) [Product Information]. Bristol-Myers Squibb: Princeton, NJ, 2003.
- Seifert, S A. Aripiprazole (Abilify®) overdose in a 2.5 year old [abstract]. J Toxicol Clin Toxicol 2003; 41(5):647–648. [CSA]
- Davenport, J D, McCarthy, M W, Buck, M L. Excessive somnolence from aripiprazole in a child. Pharmacotherapy 2004; 24(4):522–525. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schaeffer, J L, Ross, R G. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry 2002; 41:538–545. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Olfson, M, Marcus, S C, Weissman, M M, Jensen, P S. National trends in the use of psychotropic medications in children. J Am Acad Child Adolesc Psychiatry 2002; 41:514–521. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Blumer, J L, Findling, R, Kauffman, R. Pharmacokinetics, tolerability and safety of aripiprazole in children and adolescents with conduct disorder [abstract]. Clin Pharmacol Ther 2002; 71:P5.